Our Blog

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today provides a trading update ahead of results for the six months ended 31 March 2021.

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that, despite COVID-19, it is achieving stronger than anticipated growth across the second half of the year.  The Company is benefiting from continued operational leverage, generated by revenue growth and investments made to drive scale and efficiency.   

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces a trading update, confirming that the impact of COVID-19 has been modest and that IXICO expects to maintain double-digit revenue growth across FY21.

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019.  IXICO is expecting its first full year of positive earnings before interest, tax, depreciation and amortisation (“EBITDA”) since listing.  This better than forecast performance has been driven by accelerated revenue growth and builds on the breakeven performance reported in the Company’s interim statement.

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, is pleased to announce that the Company has continued to see strong growth in revenue in the second half of the year.